Enjoy complimentary customisation on priority with our Enterprise License!
The global multiple sclerosis drugs market size will grow by USD 7.79 billion during 2019-2023 at a CAGR of close to 6%. The rising prevalence of multiple sclerosis and the development of novel drugs are some of the factors expected to drive market growth. This market report provides a detailed analysis of the market by type (oral and parenteral) and geography (Asia, Europe, North America, and ROW). Also, the report analyzes the market’s competitive landscape and offers information on several market vendors including Bayer AG, Biogen, Merck KGaA, Novartis AG, and Sanofi.
Key Insights from Multiple Sclerosis Drugs Market – Global Forecast 2019-2023
See the complete table of contents and list of exhibits, as well as selected illustrations and example pages from the multiple sclerosis drugs market report
The rising prevalence of multiple sclerosis is one of the key factors expected to trigger multiple sclerosis drugs market growth in the coming years. Several factors including genetic and environmental are contributing to the rising incidence of multiple sclerosis. Prevalence of autoimmune diseases, including type 1 diabetes and certain infections, including the infectious mononucleosis also lead to a surging risk of multiple sclerosis. With the rising incidence of this health condition, the demand for MS drugs will increase significantly in the coming years which will contribute to the growth of multiple sclerosis drugs market size.
The development of novel drugs is one of the key trends expected to gain traction in the market. Researchers have already discovered drugs that slow the progression of the symptoms of secondary progressive multiple sclerosis. Furthermore, the market has also witnessed increased approvals of innovative therapies for the treatment of relapsing forms of multiple sclerosis and primary-progressive multiple sclerosis. The rising development of novel drugs coupled with the growing prevalence of the disease will drive the multiple sclerosis drugs market growth at a CAGR of close to 6% during the forecast period.
Quantitative Data
|
Qualitative Data
|
The type segment has been segregated into oral and parenteral. The parenteral segment accounted for the highest multiple sclerosis drugs market share in 2018. However, the oral type segment will gain traction and account for the largest share by the end of the forecast period. During the forecast period, the oral segment will grow at a faster pace than the overall market. The parenteral segment will grow at a slower pace than the overall market.
The increasing prevalence of multiple sclerosis and the availability of oral disease-modifying drugs are some of the factors contributing to the growth of the multiple sclerosis drugs market in the oral type segment.
North America accounted for the highest market share in 2018. Though the market’s growth in this region will be slower than the growth of the market in Asia, the region will account for the largest multiple sclerosis drugs market share throughout the forecast period. The US is a key market for multiple sclerosis drugs in this region.
The presence of major vendors and increasing awareness initiatives and patient support will fuel multiple sclerosis drugs market growth in North America.
The multiple sclerosis drugs market is moderately concentrated, and companies are launching innovative drugs for the treatment of this health condition. To help clients improve their position, this multiple sclerosis drugs market analysis report provides information on the competitive landscape and the products offered by various companies. Moreover, this multiple sclerosis drugs market research report also includes information on the upcoming trends and challenges that will influence market growth. This will help companies create strategies to make most of the upcoming growth opportunities.
The report offers a detailed analysis of several leading multiple sclerosis drugs manufacturers, including:
Multiple sclerosis drugs market by type
Multiple sclerosis drugs market by region
We can help! Our analysts can customize the market research report to meet your requirements. Get in touch
PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
PART 03: MARKET LANDSCAPE
PART 04: PIPELINE ANALYSIS
PART 05: MARKET SIZING
PART 06: FIVE FORCES ANALYSIS
PART 07: MARKET SEGMENTATION BY TYPE
PART 08: CUSTOMER LANDSCAPE
PART 09: GEOGRAPHIC LANDSCAPE
PART 10: DECISION FRAMEWORK
PART 11: DRIVERS AND CHALLENGES
PART 12: MARKET TRENDS
PART 13: VENDOR LANDSCAPE
PART 14: VENDOR ANALYSIS
PART 15: APPENDIX
PART 16: EXPLORE TECHNAVIO
Get lifetime access to our
Technavio Insights
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.